The heart and SARS-CoV-2.

David González-Calle, Rocío Eiros, Pedro L Sánchez
Author Information
  1. David González-Calle: Servicio de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), CIBERCV, Universidad de Salamanca, Salamanca, Spain.
  2. Rocío Eiros: Servicio de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), CIBERCV, Universidad de Salamanca, Salamanca, Spain.
  3. Pedro L Sánchez: Servicio de Cardiología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), CIBERCV, Universidad de Salamanca, Salamanca, Spain.

Abstract

SARS-Cov2 is currently causing a persistent Covid-19 pandemic, which poses a risk of causing long-term cardiovascular sequels in the population. The viral mechanism of cell infection through the angiotensin 2 converter enzyme receptor and the limited antiviral innate immune response are the suspected causes for a more frequent cardiovascular damage in SARS-Cov2 infection. Knowledge of: the appearance during acute infection of other cardiac conditions beyond the classical myocarditis and pericarditis), the long-term cardiac manifestations (persistent Covid-19), and the increased incidence of myocarditis and pericarditis after vaccination; it is of special interest in order to offer our patients best practices based on current scientific evidence.

Keywords

References

  1. JAMA. 2020 Mar 17;323(11):1061-1069 [PMID: 32031570]
  2. Lancet. 2020 Mar 28;395(10229):1054-1062 [PMID: 32171076]
  3. Lancet Infect Dis. 2022 Apr;22(4):e102-e107 [PMID: 34951953]
  4. Med Clin (Barc). 2013 Jan 19;140(2):70-5 [PMID: 22766060]
  5. Heart Fail Rev. 2022 Jan;27(1):251-261 [PMID: 33761041]
  6. J Thorac Imaging. 2021 Mar 1;36(2):73-83 [PMID: 33306666]
  7. Am J Cardiol. 1970 Nov;26(5):447-54 [PMID: 4920772]
  8. Eur J Intern Med. 2021 Nov;93:28-34 [PMID: 34588140]
  9. EClinicalMedicine. 2021 Aug;38:101019 [PMID: 34308300]
  10. Rev Esp Cardiol (Engl Ed). 2022 Sep;75(9):734-746 [PMID: 34866030]
  11. JAMA Cardiol. 2020 Jul 1;5(7):819-824 [PMID: 32219357]
  12. J Magn Reson Imaging. 2021 Jun;53(6):1723-1729 [PMID: 33474768]
  13. Am J Pathol. 2021 Jul;191(7):1154-1164 [PMID: 33964216]
  14. Circ Cardiovasc Imaging. 2021 Jan;14(1):e012220 [PMID: 33463366]
  15. Int J Cardiol. 2019 Nov 1;294:61-64 [PMID: 31378380]
  16. Healthcare (Basel). 2021 May 18;9(5): [PMID: 34070115]
  17. Trends Cardiovasc Med. 2021 Apr;31(3):143-160 [PMID: 33338635]
  18. Nat Commun. 2022 Apr 12;13(1):1957 [PMID: 35413949]
  19. JACC Cardiovasc Imaging. 2021 Nov;14(11):2155-2166 [PMID: 33975819]
  20. J Am Coll Cardiol. 2022 May 3;79(17):1717-1756 [PMID: 35307156]
  21. Eur Heart J. 2015 Nov 7;36(42):2921-2964 [PMID: 26320112]
  22. J Am Coll Cardiol. 2020 May 12;75(18):2352-2371 [PMID: 32201335]
  23. Rev Esp Cardiol. 1998 Jul;51(7):582-90 [PMID: 9711107]
  24. Circulation. 2020 Jul 28;142(4):342-353 [PMID: 32469253]
  25. Ann Intern Med. 2020 Aug 18;173(4):268-277 [PMID: 32374815]
  26. Ann Med Surg (Lond). 2022 Apr;76:103486 [PMID: 35291413]
  27. Vaccine. 2021 Jan 29;39(5):839-845 [PMID: 33422381]
  28. Immunol Res. 2021 Apr;69(2):205-211 [PMID: 33786700]
  29. J Cardiovasc Electrophysiol. 2020 Dec;31(12):3086-3096 [PMID: 33022765]
  30. N Engl J Med. 2021 Sep 16;385(12):1078-1090 [PMID: 34432976]
  31. Clin Infect Dis. 2022 Nov 14;75(10):1688-1697 [PMID: 35403679]
  32. Circulation. 2021 Aug 10;144(6):471-484 [PMID: 34281357]
  33. Med Clin (Engl Ed). 2021 Oct 8;157(7):e293-e294 [PMID: 34632070]
  34. JAMA. 2021 Jan 19;325(3):254-264 [PMID: 33464336]
  35. JAMA Cardiol. 2022 Jun 1;7(6):600-612 [PMID: 35442390]
  36. J Am Coll Cardiol. 2020 Oct 27;76(17):1965-1977 [PMID: 33092732]
  37. Infection. 2022 Feb;50(1):285-286 [PMID: 34519974]
  38. Thromb Res. 2020 Jul;191:145-147 [PMID: 32291094]
  39. Heart Rhythm. 2020 Sep;17(9):1439-1444 [PMID: 32585191]
  40. J Evid Based Med. 2022 Mar;15(1):30-38 [PMID: 35416437]
  41. Eur Heart J. 2021 May 14;42(19):1866-1878 [PMID: 33596594]
  42. J Am Coll Cardiol. 2020 Oct 27;76(17):2011-2023 [PMID: 33092737]
  43. JAMA. 2003 Jun 25;289(24):3278-82 [PMID: 12824209]
  44. Nat Med. 2022 Mar;28(3):583-590 [PMID: 35132265]
  45. Clin Infect Dis. 2021 Dec 6;73(11):e4058-e4063 [PMID: 33252665]
  46. Front Cardiovasc Med. 2022 Mar 09;9:860198 [PMID: 35355961]
  47. Rev Esp Cardiol (Engl Ed). 2022 May;75(5):444-446 [PMID: 34824040]
  48. Heart. 2020 Aug;106(15):1132-1141 [PMID: 32354800]
  49. J Magn Reson Imaging. 2022 Mar;55(3):866-880 [PMID: 34309139]
  50. Turk Thorac J. 2022 Mar;23(2):89-96 [PMID: 35404239]
  51. Eur Heart J Cardiovasc Imaging. 2020 Sep 1;21(9):949-958 [PMID: 32556199]
  52. Circ Heart Fail. 2020 Oct;13(10):e007485 [PMID: 32844662]
  53. BMJ. 2021 Jul 26;374:n1648 [PMID: 34312178]
  54. Sci Rep. 2021 Aug 9;11(1):16144 [PMID: 34373540]
  55. MMWR Morb Mortal Wkly Rep. 2003 Jul 11;52(27):639-42 [PMID: 12855946]
  56. Heart Fail Rev. 2022 Jul;27(4):1341-1353 [PMID: 34215924]
  57. Nat Rev Cardiol. 2021 Mar;18(3):169-193 [PMID: 33046850]
  58. BMJ. 2020 May 29;369:m1996 [PMID: 32471884]

Word Cloud

Created with Highcharts 10.0.0infectionSARS-Cov2causingpersistentCovid-19long-termcardiovascularcardiacmyocarditispericarditismanifestationsSARS-CoV-2COVID-19currentlypandemicposesrisksequelspopulationviralmechanismcellangiotensin2converterenzymereceptorlimitedantiviralinnateimmuneresponsesuspectedcausesfrequentdamageKnowledgeof:appearanceacuteconditionsbeyondclassicalincreasedincidencevaccinationspecialinterestorderofferpatientsbestpracticesbasedcurrentscientificevidenceheartvaccineCardiovascularPersistentCOVID

Similar Articles

Cited By